Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations
Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations
复制标题
DOI：
10.1002/mds.23040
复制
发表时间：
2010-05-15
影响因子：
8.6
通讯作者：
Stacy, Mark
中科院分区：
文献类型：
--
作者：
Hersh, Bonnie P.;Earl, Nancy L.;Stacy, Mark
We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in "off" time (adjusted mean treatment difference [AMTD] - 0.7 hours; 95% confidence interval [Cl], -1.1, -0.2; P = 0.0029), and "on" time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, -3.1; 95%CI, -4.4, -1.8; P < 0.0001), activities of daily living score (AMTD, -1.1; 95%CI, -1.7, -0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation. (C) 2010 Movement Disorder Society
